ATE209491T1 - Stabilisierung von säureempfindluchen benzimidazolen unter verwendung von aminosäure/cyclodextrin kombinationen - Google Patents
Stabilisierung von säureempfindluchen benzimidazolen unter verwendung von aminosäure/cyclodextrin kombinationenInfo
- Publication number
- ATE209491T1 ATE209491T1 AT98919099T AT98919099T ATE209491T1 AT E209491 T1 ATE209491 T1 AT E209491T1 AT 98919099 T AT98919099 T AT 98919099T AT 98919099 T AT98919099 T AT 98919099T AT E209491 T1 ATE209491 T1 AT E209491T1
- Authority
- AT
- Austria
- Prior art keywords
- acid
- benzimidazoles
- stabilization
- amino acid
- sensitivity
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 230000035945 sensitivity Effects 0.000 title 1
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97104200 | 1997-03-13 | ||
| PCT/EP1998/001478 WO1998040069A2 (en) | 1997-03-13 | 1998-03-13 | Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE209491T1 true ATE209491T1 (de) | 2001-12-15 |
Family
ID=8226585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98919099T ATE209491T1 (de) | 1997-03-13 | 1998-03-13 | Stabilisierung von säureempfindluchen benzimidazolen unter verwendung von aminosäure/cyclodextrin kombinationen |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6248758B1 (de) |
| JP (1) | JP4608031B2 (de) |
| KR (1) | KR100563764B1 (de) |
| CN (1) | CN1113649C (de) |
| AT (1) | ATE209491T1 (de) |
| AU (1) | AU731186B2 (de) |
| BR (1) | BR9808581A (de) |
| CA (1) | CA2282513C (de) |
| CZ (1) | CZ291842B6 (de) |
| DE (1) | DE69802688T3 (de) |
| DK (1) | DK0991407T4 (de) |
| ES (1) | ES2167891T5 (de) |
| HU (1) | HU225587B1 (de) |
| IL (1) | IL131651A0 (de) |
| NO (1) | NO327212B1 (de) |
| NZ (1) | NZ337592A (de) |
| PL (1) | PL191570B1 (de) |
| PT (1) | PT991407E (de) |
| SI (1) | SI0991407T2 (de) |
| SK (1) | SK284811B6 (de) |
| TR (1) | TR199902233T2 (de) |
| WO (1) | WO1998040069A2 (de) |
| ZA (1) | ZA982155B (de) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174548B1 (en) * | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| JP4127740B2 (ja) * | 1998-04-20 | 2008-07-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定化したベンズイミダゾール系化合物含有組成物 |
| US6733778B1 (en) * | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| PT1018340E (pt) * | 1999-01-06 | 2003-12-31 | Tecnimede Sociedade Tecnico Medicinal Sa | Complexos de inclusao de sais de aminoacidos de derivados do benzimidazol com ciclodextrinas, sua preparacao e formulacoes farmaceuticas que os contem |
| IL130602A0 (en) * | 1999-06-22 | 2000-06-01 | Dexcel Ltd | Stable benzimidazole formulation |
| US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
| DE19959419A1 (de) | 1999-12-09 | 2001-06-21 | Ratiopharm Gmbh | Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung |
| CN1322850C (zh) * | 2000-06-02 | 2007-06-27 | 沈阳药科大学 | 盐酸尼卡地平粉针剂及其制备方法 |
| WO2002026210A2 (en) * | 2000-09-29 | 2002-04-04 | Geneva Pharmaceuticals Inc. | Proton pump inhibitor formulation |
| CN1262274C (zh) * | 2000-11-14 | 2006-07-05 | 生命健康科学有限公司 | 磷酸盐衍生物复合物 |
| AUPR549901A0 (en) | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
| GB2376231A (en) * | 2001-06-06 | 2002-12-11 | Cipla Ltd | Benzimidazole-cyclodextrin inclusion complex |
| BR0211673A (pt) * | 2001-07-27 | 2004-07-13 | Vital Health Sciences Pty Ltd | Terapia dermal utilizando derivados de fosfato de agentes de transferência de elétrons |
| AUPR684801A0 (en) * | 2001-08-06 | 2001-08-30 | Vital Health Sciences Pty Ltd | Supplement therapy |
| GB2379854B (en) * | 2001-09-19 | 2006-04-19 | Walcom Animal Science | Dairy cow feed and the use thereof |
| ATE487456T1 (de) * | 2001-12-13 | 2010-11-15 | Vital Health Sciences Pty Ltd | Transdermaler transport von verbindungen |
| US20050171057A1 (en) * | 2002-01-15 | 2005-08-04 | Altana Pharma Ag | Pantoprazole cyclodextrin inclusion complexes |
| ITMI20021074A1 (it) * | 2002-05-20 | 2003-11-20 | Actimex S R L | Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione |
| US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
| CA2494716A1 (en) * | 2002-08-02 | 2004-02-19 | Ratiopharm Gmbh | Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation |
| AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| US20040028737A1 (en) * | 2002-08-12 | 2004-02-12 | Kopran Research Laboratories Limited | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| ITMI20022549A1 (it) * | 2002-12-02 | 2004-06-03 | Actimex S R L | Composizione quaternaria comprendente come sostanza attiva la propolis. |
| US20040109920A1 (en) * | 2002-12-04 | 2004-06-10 | Bioactives Llc | Coated carotenoid cyclodextrin complexes |
| CA2513427C (en) * | 2003-01-17 | 2012-03-27 | Vital Health Sciences Pty Ltd. | Compounds having anti-proliferative properties |
| US20040166162A1 (en) * | 2003-01-24 | 2004-08-26 | Robert Niecestro | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
| AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| ATE495730T1 (de) | 2004-03-03 | 2011-02-15 | Vital Health Sciences Pty Ltd | Alkaloid-formulierungen |
| KR20050105565A (ko) * | 2004-04-30 | 2005-11-04 | 에스케이케미칼주식회사 | 저장안정성이 우수한 벤즈이미다졸 유도체 함유 포접복합체 및 이의 제조방법 |
| WO2005112637A1 (en) * | 2004-05-14 | 2005-12-01 | Decode Chemistry, Inc. | Formulations for non-parenteral use including hydrophobic cyclodextrins |
| US20060058276A1 (en) * | 2004-07-15 | 2006-03-16 | Oded Friedman | Processes for the preparation and purification of rocuronium bromide |
| US20090004166A1 (en) * | 2004-08-03 | 2009-01-01 | Simon Michael West | Carrier For Enternal Administration |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005008412A1 (de) * | 2005-02-24 | 2006-09-07 | Ratiopharm Gmbh | Piperazinsalz des Omeprazols und dessen Enantiomere |
| US20090239827A1 (en) * | 2005-03-03 | 2009-09-24 | Esra Ogru | Compounds having lipid lowering properties |
| EP2548581A3 (de) | 2005-06-17 | 2013-02-20 | Vital Health Sciences Pty Ltd. | Träger mit einem oder mehreren Di- bzw. Mono-(Elektrontransfermittel) Phosphatderivaten oder Komplexen davon |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2007070981A1 (en) * | 2005-12-23 | 2007-06-28 | Vital Health Sciences Pty Ltd | Compounds having cytokine modulating properties |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
| EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
| CA2654402A1 (en) * | 2006-06-01 | 2007-12-06 | Adel Penhasi | Multiple unit pharmaceutical formulation |
| US7840305B2 (en) | 2006-06-28 | 2010-11-23 | 3M Innovative Properties Company | Abrasive articles, CMP monitoring system and method |
| EP3542801A1 (de) * | 2007-08-17 | 2019-09-25 | Boehringer Ingelheim International GmbH | Purinderivate zur verwendung bei der behandlung von fap-bedingten erkrankungen |
| PE20140960A1 (es) * | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| CN102076330A (zh) * | 2008-06-30 | 2011-05-25 | 默沙东公司 | 替卡格泮钾的固体剂量制剂 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| CN103816158A (zh) * | 2008-08-15 | 2014-05-28 | 勃林格殷格翰国际有限公司 | 用于治疗fab-相关疾病的嘌呤衍生物 |
| CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CN107011345A (zh) | 2008-12-23 | 2017-08-04 | 勃林格殷格翰国际有限公司 | 有机化合物的盐形式 |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| EP2504002B1 (de) | 2009-11-27 | 2019-10-09 | Boehringer Ingelheim International GmbH | Behandlung von genotypisierten diabetes-patienten mit dpp-iv-hemmern wie etwa linagliptin |
| AU2011213557B2 (en) | 2010-02-05 | 2015-05-07 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| MX2012011355A (es) | 2010-03-30 | 2012-11-30 | Phosphagenics Ltd | Parche de suministro transdermico. |
| KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
| KR20200028498A (ko) | 2010-06-24 | 2020-03-16 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| US8383663B2 (en) * | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| WO2012122586A1 (en) | 2011-03-15 | 2012-09-20 | Phosphagenics Limited | New composition |
| HUE061596T2 (hu) | 2011-07-15 | 2023-07-28 | Boehringer Ingelheim Int | Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben |
| CN102584633B (zh) * | 2011-12-16 | 2013-07-03 | 山东大学 | 一种赖氨酸α-氨基的苄氧羰基高效选择性保护方法及其产品 |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| ES2929025T3 (es) | 2012-05-14 | 2022-11-24 | Boehringer Ingelheim Int | Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (de) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medizinische verwendung eines dpp-4-inhibitors |
| EP3288556A4 (de) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Oral zerfallende zusammensetzungen |
| TWI721997B (zh) * | 2015-07-13 | 2021-03-21 | 日商協和發酵生化股份有限公司 | 含高含量精胺酸之錠劑 |
| CN114712308A (zh) | 2015-12-09 | 2022-07-08 | 磷肌酸有限公司 | 药物制剂 |
| CN106924179B (zh) * | 2015-12-29 | 2021-04-30 | 成都康弘药业集团股份有限公司 | 一种含有富马酸沃诺拉赞的液体制剂及其制备方法 |
| BR112018072401A2 (pt) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinações de linagliptina e metformina |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| KR101829685B1 (ko) * | 2016-07-28 | 2018-02-19 | 씨제이헬스케어 주식회사 | 안정성 및 용해도가 개선된 주사용 조성물 |
| KR101829705B1 (ko) * | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | 안정성이 향상된 주사용 조성물 |
| EP3558903B1 (de) | 2016-12-21 | 2024-07-03 | Avecho Biotechnology Limited | Verfahren zur phosphorylierung eines komplexen alkohols |
| CN108324957B (zh) * | 2018-04-20 | 2021-04-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | 一种s-羧甲基-l-半胱氨酸包合物及其肠溶制剂组合物 |
| CN116585283B (zh) * | 2023-05-26 | 2024-11-22 | 桂林华信制药有限公司 | 兰索拉唑肠溶胶囊及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3427787A1 (de) * | 1984-07-27 | 1986-01-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel |
| DE3427786A1 (de) * | 1984-07-27 | 1986-01-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Inklusionskomplexe von benzimidazolderivaten mit cyclodextrinen, deren herstellung und arzneimittel |
| US5433959A (en) * | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
| KR920008161B1 (ko) * | 1990-02-19 | 1992-09-24 | 한미약품공업주식회사 | 오메프라졸 경구용 약제의 제조방법 |
| KR930000861B1 (ko) * | 1990-02-27 | 1993-02-08 | 한미약품공업 주식회사 | 오메프라졸 직장투여 조성물 |
| US5232706A (en) * | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
| JPH05194225A (ja) * | 1991-11-07 | 1993-08-03 | Yoshitomi Pharmaceut Ind Ltd | 安定化された抗潰瘍剤含有製剤 |
| TW224049B (de) * | 1991-12-31 | 1994-05-21 | Sunkyong Ind Ltd | |
| AU4513393A (en) * | 1992-07-17 | 1994-02-14 | Astra Aktiebolag | Pharmaceutical composition containing antiulcer agent |
| PT1078628E (pt) * | 1994-07-08 | 2009-01-27 | Astrazeneca Ab | Forma de dosagem em comprimidos com unidades múltiplas |
| SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
| AU5780696A (en) * | 1995-06-02 | 1996-12-18 | Takeda Chemical Industries Ltd. | Stabilized composition comprising an antiulcerative benzimid azole |
| JPH0948730A (ja) * | 1995-06-02 | 1997-02-18 | Takeda Chem Ind Ltd | 水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物 |
-
1998
- 1998-03-13 IL IL13165198A patent/IL131651A0/xx not_active IP Right Cessation
- 1998-03-13 KR KR1019997008327A patent/KR100563764B1/ko not_active Expired - Fee Related
- 1998-03-13 SK SK1209-99A patent/SK284811B6/sk not_active IP Right Cessation
- 1998-03-13 SI SI9830069T patent/SI0991407T2/xx unknown
- 1998-03-13 BR BR9808581-6A patent/BR9808581A/pt not_active Application Discontinuation
- 1998-03-13 US US09/319,895 patent/US6248758B1/en not_active Expired - Lifetime
- 1998-03-13 CZ CZ19993128A patent/CZ291842B6/cs not_active IP Right Cessation
- 1998-03-13 DE DE69802688T patent/DE69802688T3/de not_active Expired - Lifetime
- 1998-03-13 NZ NZ337592A patent/NZ337592A/xx not_active IP Right Cessation
- 1998-03-13 AT AT98919099T patent/ATE209491T1/de active
- 1998-03-13 CN CN98803296A patent/CN1113649C/zh not_active Expired - Fee Related
- 1998-03-13 JP JP53923798A patent/JP4608031B2/ja not_active Expired - Fee Related
- 1998-03-13 AU AU72070/98A patent/AU731186B2/en not_active Ceased
- 1998-03-13 ZA ZA982155A patent/ZA982155B/xx unknown
- 1998-03-13 DK DK98919099T patent/DK0991407T4/da active
- 1998-03-13 PL PL335571A patent/PL191570B1/pl unknown
- 1998-03-13 WO PCT/EP1998/001478 patent/WO1998040069A2/en not_active Ceased
- 1998-03-13 HU HU0002364A patent/HU225587B1/hu not_active IP Right Cessation
- 1998-03-13 CA CA002282513A patent/CA2282513C/en not_active Expired - Fee Related
- 1998-03-13 TR TR1999/02233T patent/TR199902233T2/xx unknown
- 1998-03-13 ES ES98919099T patent/ES2167891T5/es not_active Expired - Lifetime
- 1998-03-13 PT PT98919099T patent/PT991407E/pt unknown
-
1999
- 1999-09-10 NO NO19994409A patent/NO327212B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE209491T1 (de) | Stabilisierung von säureempfindluchen benzimidazolen unter verwendung von aminosäure/cyclodextrin kombinationen | |
| ATE223232T1 (de) | Tocopherolzusammensetzungen zur abgabe von biologisch aktiven substanzen | |
| NO20011721D0 (no) | N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor | |
| CY1110906T1 (el) | Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης | |
| NO971889L (no) | Forbindelser og sammensetninger for levering av aktive midler | |
| DK0994710T4 (da) | Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin | |
| CY1111698T1 (el) | Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης | |
| CY1108914T1 (el) | Μητρα για παρατεταμενη, αμεταβλητη και ανεξαρτητη απελευθερωση δραστικων ενωσεων | |
| CY1114000T1 (el) | Σταθεροποιημενα διαλυματα τεριπαρατιδης | |
| TR200200518T2 (tr) | Felç, Diyabet ve/veya Konjesif Kalp Yetmezliğinin Önlenmesinde Kullanılan Farmolojik Formulasyonlar | |
| EE05054B1 (et) | 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis | |
| DE69933671D1 (de) | Adenosin a1 antagonisten gegen männliche sterilität | |
| BR0001661A (pt) | Composições pesticidas | |
| SE9902742D0 (sv) | New pharmaceutical formultion | |
| DK0931082T3 (da) | Nodulisporinsyrederivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0991407 Country of ref document: EP |